Acquisition

Gedeon Richter to buy Mayne Pharma in US$390.8M cash deal at 99% premium

What's the deal? Hungary's Gedeon RichterDealroom has a profile for this one. Try Dealroom → has agreed to acquire ASX-listed Mayne PharmaDealroom has a profile for this one. Try Dealroom → (ASX:MYX) for US$4.14 a share in cash, valuing the drugmaker's equity at about US$390.8M. The deal is structured as a scheme of arrangement, with Richter taking a 100% stake. Mayne shares jumped 80.6% to US$3.75 after the announcement.

Why the attention? The price marks a 99.4% premium to Mayne's November 16 close — nearly double its prior value — and a 124% premium to its 30-day volume weighted average price. Shareholders representing 22.14% of the company, including Funicular Funds, Bruce Mathieson and Trium Capital, have indicated they will vote in favour.

What's the endgame? Richter, which operates in around 50 countries, sees Mayne's US commercial presence as a platform to expand its women's health business. Mayne has narrowed its focus to US women's health, dermatology and its DistributeRx platform.

The context: The bid follows a bruising collapse of Mayne's 2025 sale to US-based CosetteDealroom has a profile for this one. Try Dealroom →, which was blocked after a dispute over Mayne's Australian factory. Earlier this month, Mayne agreed to sell its international and Australian manufacturing business to Evaris Pharma for US$35.9M, leaving the US-focused assets Richter wants.

What could go wrong? Payment is not assured. The Evaris sale must complete and clear the Australian Competition and Consumer Commission; the Richter scheme also needs Foreign Investment Review Board clearance, US antitrust approval, shareholder and court sign-off. Mayne's convertible notes, maturing December 31, 2026, add a further moving part.

The scheme is fully funded from Richter's internal cash, so there is no financing condition. The board recommends it unanimously, subject to no superior proposal and an independent expert deeming it in shareholders' best interests. The parties target implementation in early 2027.

The signal: The unusually large premium, set against the failed Cosette deal, underscores how a focused US women's-health and dermatology business can command renewed appeal from a global acquirer seeking a foothold in the American market.

Read more: kalkinemedia.com

Image credit: Generated with Gemini

More top stories